Dr. David Johnston to Drive Innovation for Biopharmaceutical Clients
WILMINGTON, N.C., (August 8, 2013) – Pharmaceutical Product Development, LLC (PPD) today announced it has appointed David Johnston, Ph.D., as executive vice president of global laboratory services. Dr. Johnston directs PPD’s industry-leading, comprehensive laboratory services, including bioanalytical, vaccines and biologics, current good manufacturing practice (cGMP) and central laboratories.
“David brings extensive leadership experience as well as scientific, medical and operational expertise,” said William Sharbaugh, chief operating officer of PPD. “As pharmaceutical companies seek to increase productivity and reduce clinical development expense, I am confident David will help us drive innovative strategies as we continue integrating laboratory services with our Phase I-IV offerings to provide clients end-to-end value-chain capabilities.”
With labs in Asia, Europe and North America, PPD’s laboratory services are designed to increase speed and precision to accelerate decision-making for clients. The company’s comprehensive range of lab services spans small and large molecules.
A biopharmaceutical industry veteran, Johnston joins PPD from LabCorp, where he served most recently as senior vice president and global head of the clinical trials business. He holds a bachelor’s degree in biology from the University of North Carolina at Greensboro and earned a doctorate in microbiology and immunology from the University of North Carolina at Chapel Hill.
Contacts
Media:
Lee Kennedy
+1 919 456 5350
[email protected]
Investors:
Luke Heagle
+1 910 558 7585
[email protected]
About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.